1461094608-e425f09b-8e5d-4b46-8b29-77c99383774d

1. A method of converting a stream of databits of a binary information signal into a stream of databits of a constrained binary channel signal, wherein the stream of databits of the binary information signal is divided into n-bit information words, said information words being converted into m1-bit channel words in accordance with a channel code C1, or m2-bit channel words, in accordance with a channel code C2, where m1, m2 and n are integers for which it holds that m2>m1n, wherein the m2-bit channel word is chosen from at least two m2-bit channel words, at least two of which have opposite parities, the concatenated m1-bit channel words and the m2-bit channel words complying with a runlength constraint of the binary channel signal,
characterized in that
the method comprises the repetitive andor alternate steps of:
selecting the m1-bit channel word from a set out of a plurality of sets of m1-bit channel words, each set comprising only m1-bit channel words having a beginning part out of a subset of beginning parts of the m1-bit channel words, each set being associated with a coding state of channel code C1, the coding state being established in dependence upon an end part of the preceding channel word,

or:
selecting the m2-bit channel word from a set out of a plurality of sets of m2-bit channel words, each set comprising only m2-bit channel words having a beginning part out of a subset of beginning parts of the m2-bit channel words belonging to said set, each set being associated with a coding state of channel code C2, the coding state being established in dependence upon an end part of the preceding channel word,

the end parts of the m1-bit channel words in a coding state of channel code C1 and the beginning parts of the m2-bit channel words in a set of channel code C2 being arranged to comply with said runlength constraint.
2. A method according to claim 1, characterized in that the number of coding states of channel code C1 is equal to the number of coding states of channel code C2.
3. A method according to claim 1 or 2, characterized in that the end part of any m1-bit channel word has a multiplicity y1, the multiplicity y1 being the number of different states of the channel code C1 said end part may establish, and that the end part of any m2-bit channel word has a multiplicity y2, the multiplicity y2 being the number of states of the channel code C2 said end part may establish and in that y1y2 if the end part of the m1-bit channel word is equal to the end part of the m2-bit channel word.
4. A method according to claim 1, 2 or 3, characterized in that said at least two m2-bit channel words establish the same state.
5. A method according to claim 1, characterized in that the sets of channel words of channel code C1 and the sets of channel words of channel code C2 are arranged that binary channel signal formed by the concatenated m1-bit channel words and the m2-bit channel words comply with a d2 constraint and a k10 constraint.
6. A method according to claim 1 or 5, characterized in that the sets of channel words of channel code C1 and the coding states of channel code C2 are arranged that binary channel signal formed by the concatenated m1-bit channel words and the m2-bit channel words comply with a Repeated-Minimum-Runlength-Limitation6 constraint on the binary channel.
7. A method according to claim 1, characterized in that n8, m115, m217.
8. A method according to claim 1, 2, 3 or 4, characterized in that the ratio between the number of m1-bit channel words and the number of m2-bit channel words is determined in dependence of a chosen measure of DC-control.
9. A method according to claim 1, characterized in that the coding state is further being established in dependence upon the n-bit information word, thereby allowing to distinguish this n-bit information word by detecting the coding state.
10. A method as claimed in claim 1, 2, 3 or 4, characterized in that the coding states of channel code C1 and the coding states of channel code C2 are further arranged that a limited number of channel words is substituted for other channel words or patterns, these other channel words or patterns not belonging to the sets of channel words of channel code C1 and channel code C2.
11. A device for encoding a stream of databits of a binary information signal into a stream of databits of a constrained binary channel signal, for performing one of the methods as claimed, the device comprising an n-to-m1-bit converter for converting the n-bit information words into m1-bit channel words, an n-to-m2-bit converter for converting the n-bit information words into m2-bit channel words, state-establishing means for establishing a coding state of the m1-bit channel words and of the m2-bit channel words, which n-to-m1 bit converter is further arranged for selecting the m1-bit channel word depending on the end part of the preceding channel word, which n-to-m2 bit converter is further arranged for selecting the m2-bit channel word depending on the end part of the preceding channel word.
12. A device for encoding according to claim 11, characterized in that the device further comprises writing means for writing an information pattern on a record carrier.
13. A signal comprising a stream of databits of a constrained binary channel signal, obtained after carrying out one of the methods as claimed.
14. A record carrier on which the signal as claimed is recorded in a track, in which information patterns represent the signal portions, which information patterns comprise first and second parts, alternating in the direction of the track, the first parts presenting detectable properties and the second parts presenting detectable properties which are distinguishable from the first properties, the parts having the first properties representing bit cells having the first logic value and the parts having the second properties representing the bit cells having the second logic value.
15. A device for decoding a stream of databits of a constrained binary channel signal into a stream of databits of a binary information signal, the device comprising converting means for converting the signal as claimed into a bit string of bits having a first or a second value, the signal containing the m1-bit channel words and the m2-bit channel words, the bit string comprising the n-bit information words, the converting means being arranged to convert the m1-bit channel words and m2-bit channel words into n-bit information words, wherein one information word is assigned to one channel word to be converted.
16. A device for decoding according to claim 15, characterized in that the device further comprises reading means for reading out an information pattern from a record carrier.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An orthopedic interface comprising a planar 3D textile with a top and a bottom that are held at a distance from each other by supporting threads and connected to each other, the bottom of the 3D textile being designed to bear on the skin of an interface user, characterized in that the surface of the bottom (21) facing the skin is provided at least partially with an adhesive coating (23).
2. The orthopedic interface as claimed in claim 1, characterized in that the top (22) facing away from the skin is provided at least partially with a coating (23).
3. The orthopedic interface as claimed in claim 1, characterized in that the coating (23) is composed of silicone, polyurethane andor a copolymer.
4. The orthopedic interface as claimed in claim 1, characterized in that the coating (23) is electrically conductive.
5. The orthopedic interface as claimed in claim 1, characterized in that the coating (23) is applied in areas set apart from one another, in particular in the shape of strips, dots, rings, or in other shapes.
6. The orthopedic interface as claimed in claim 1, characterized in that the coating (23) is applied over the whole surface.
7. The orthopedic interface as claimed in claim 1, characterized in that the coating (23) is air-permeable andor moisture-permeable.
8. The orthopedic interface as claimed in claim 1, characterized in that the processed threads of the 3D textile (2) are at least partially coated.
9. The orthopedic interface as claimed in claim 1, characterized in that silver threads are woven or spun into the 3D textile (2), particularly into the bottom (21).
10. The orthopedic interface as claimed in claim 1, characterized in that the top (22) has a structure that has less resistance in the direction of insertion of the interface (1) than counter to the direction of insertion.
11. he orthopedic interface as claimed in claim 10, characterized in that a nap velour is formed on or applied to the top (22).
12. The orthopedic interface as claimed in claim 1, characterized in that it is designed as a liner for bearing on an amputation stump.
13. The orthopedic interface as claimed in claim 1, characterized in that it is designed as a flexible socket or as a flexible socket part with receiving means for orthotic or prosthetic components.
14. The orthopedic interface as claimed in claim 1, characterized in that it is anatomically preshaped.
15. The orthopedic interface as claimed in claim 1, characterized in that the 3D textile is designed as a spaced knitted fabric.
16. The orthopedic interface as claimed in claim 1, characterized in that the bottom (21) is designed as a lower textile and the top (22) is designed as an upper textile.
17. The orthopedic interface as claimed in claim 1, characterized in that electrodes (5) are applied to the bottom (21) or worked into the 3D textile (2).
18. The orthopedic interface as claimed in claim 1, characterized in that the 3D textile (2) andor the coating (23) are made antibacterial, in particular with vapor deposition of silver andor addition of silver ions.
19. A system composed of an orthopedic interface (1) as claimed in claim 1, and of an orthotic or prosthetic device (3, 4).
20. The system as claimed in claim 19, characterized in that the prosthetic or orthotic device (3, 4) has a substantially dimensionally stable receiver (13) with a structure that has less resistance in the direction of insertion of the interface (1) than counter to the direction of insertion.
21. The system as claimed in claim 20, characterized in that the structure is designed as a nap velour.
22. The system as claimed in claim 19, characterized in that the prosthetic or orthotic device (3, 4) has a substantially dimensionally stable receiver (3) with a coating (33) on the inside surface (31).
23. The system as claimed in claim 22, characterized in that the coating (33) is designed as a nap velour.

1461094597-83ce3286-a734-4e74-9dee-9c79aaae9c9f

1. A method of creating a logical profile for physical devices in a system to interface with a monitoring system, the method comprising:
selecting a profile identity;
selecting a plurality of physical devices from the system, the physical devices including an output or an input;
defining an input or output for at least one of the plurality of selected physical devices as a tag; and
wherein the plurality of selected physical devices are represented to the monitoring system by the profile identity and the at least one tag of the selected physical devices.
2. The method of claim 1, wherein the tag is assigned to any physical device type that has the defined input or output.
3. The method of claim 1, wherein the physical devices include power monitoring devices and power control devices.
4. The method of claim 1, wherein the selected plurality of physical devices include a controller and slave devices coupled to the controller.
5. The method of claim 1, wherein the logical profile is matched to additional devices on the system to represent the additional devices.
6. The method of claim 1, further comprising creating a functional block for the logical profile, the functional block including a plurality of tags, the functional block applied to all physical devices having inputs or outputs defined by the plurality of tags, the functional blocks defining the addresses of the inputs or outputs with an offset for each device represented by the function block.
7. The method of claim 1, wherein the tag includes real time data, an alarm signal or control signals.
8. The method of claim 1, wherein the plurality of selected physical devices includes a processing device calculating data received from another one of the plurality of selected physical devices and the tag defines the calculated data.
9. A monitoring system comprising:
a plurality of physical devices having inputs or outputs;
a master controller coupled to the plurality of physical devices; and
a monitoring system on the master controller, the monitoring system interfacing with the plurality of devices via a logical profile representing a selected number of physical devices from the plurality of physical devices, the logical profile including at least one tag defining an input or output for one of the selected physical devices.
10. The system of claim 9, wherein the tag is assigned to any physical device type that has the defined input or output.
11. The system of claim 9, wherein the physical devices include power monitoring devices and power control devices.
12. The system of claim 9, wherein the selected plurality of physical devices includes a controller and slave devices coupled to the controller.
13. The system of claim 9, wherein the logical profile is matched to additional devices on the system to represent the additional devices.
14. The system of claim 9, wherein the logical profile includes a functional block including a plurality of tags, the functional block applied to all physical devices having inputs or outputs defined by the plurality of tags, the functional blocks defining the addresses of the inputs or outputs with an offset for each device represented by the function block.
15. The system of claim 9, wherein the tag includes real time data, an alarm signal or control signals.
16. The system of claim 9, further comprising a network coupled to the master controller and the plurality of physical devices.
17. The system of claim 9, wherein the plurality of selected physical devices includes a processing device calculating data received from another one of the plurality of selected physical devices and the tag defines the calculated data.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A pharmaceutical formulation comprising an immediate release component and an extended release component wherein, when said formulation is administered to a subject, said formulation provides eight-hour bioequivalence of APAP compared to two consecutive administrations of one-half equivalent dose concentrations of APAP at a four-hour interval.
2. A pharmaceutical formulation according to claim 1, wherein APAP is present in said pharmaceutical formation at a dosage strength ranging from about 325 to about 1300 mg in one or more unit dosage forms.
3. A pharmaceutical formulation according to claim 1, wherein APAP is present in the formulation at a dosage strength comprising 325, 500, or 650 mg.
4. A pharmaceutical formulation according to claim 1, wherein at least one active pharmaceutical ingredient is added to at least one of said immediate release component or said extended release component or both.
5. A pharmaceutical formulation according to claim 4, wherein the at least one active pharmaceutical ingredient is selected from the group consisting of an opioid or opioid-like compound, a non-steroidal anti-inflammatory drug (NSAID), a cyclooxygenase-II (COX-2) inhibitor, a glycine receptor antagonist, an antitussive, an expectorant, a decongestant, an antihistamine and mixtures thereof.
6. A pharmaceutical formulation according to claim 5, wherein said active pharmaceutical ingredient is an opioid or opioid-like compound.
7. A pharmaceutical formulation according to claim 6, wherein said opioid or opioid-like compound is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, and salts of any of the foregoing.
8. A pharmaceutical formulation according to claim 7, wherein said opioid or opioid-like compounds is selected from the group consisting of hydrocodone, morphine, hydromorphone, oxycodone, codeine, levorphanol, meperidine, methadone, or salts thereof, and mixtures thereof.
9. A pharmaceutical formulation according to claim 8, wherein said active pharmaceutical ingredient is a propoxyphene salt.
10. A pharmaceutical formulation according to claim 9, wherein the propoxyphene salt is selected from the group consisting of propoxyphene napsylate and propoxyphene hydrochloride.
11. A pharmaceutical formulation according to claim 9, wherein the propoxyphene salt is present in the immediate release and extended release components as a weight ratio comprising 50%IR:50%ER, 45%IR:55% ER, or 40%IR:60%ER.
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. (canceled)
19. (canceled)
20. A pharmaceutical formulation according to claim 1, wherein the immediate release component comprises APAP, at least one disintegrant, and, optionally, one or more binders.
21. (canceled)
22. (canceled)
23. (canceled)
24. A pharmaceutical formulation according to claim 1, wherein the extended release component at least one controlled release matrix polymer, and, optionally, one or more APIs.
25. (canceled)
26. (canceled)
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)
31. (canceled)
32. (canceled)
33. (canceled)
34. (canceled)
35. (canceled)
36. (canceled)
37. (canceled)
38. (canceled)
39. (canceled)
40. (canceled)
41. (canceled)
42. (canceled)
43. (canceled)
44. (canceled)
45. (canceled)
46. (canceled)
47. (canceled)
48. (canceled)
49. (canceled)
50. (canceled)
51. (canceled)
52. A pharmaceutical formulation in unit dosage form comprising per dosage unit an amount of APAP within a range from about 325 to about 1300 mg of a composition comprising an immediate release component and an extended release component wherein, when said formulation is administered to a subject, said formulation provides eight-hour bioequivalence of APAP compared to two consecutive administrations of one-half equivalent dose concentrations of APAP at a four-hour interval, and wherein said formulation in unit dosage form being adapted for oral administration.
53. (canceled)
54. (canceled)
55. A pharmaceutical formulation comprising a first active ingredient which is APAP and an optional second active ingredient selected from the group consisting of one or more opiod or opiod-like compound wherein, when said formulation is administered to a subject in a single dose and at a total dosage strength of 1300 mg APAP under fasting conditions, the maximum plasma concentration (Cmax) of the APAP following administration is in the range from about 5.89_ugmL to about 9.52_ugmL.
56. (canceled)
57. (canceled)
58. (canceled)
59. (canceled)
60. (canceled)
61. (canceled)
62. (canceled)
63. (canceled)
64. A pharmaceutical formulation comprising a blend of (a) an immediate release component comprising acetaminophen, an optional water soluble binder, and at least one disintegrant; and (b) an extended release component comprising at least one controlled release matrix polymer, and one or more optional fillers, and one or more optional wicking agents.
65. (canceled)
66. (canceled)
67. (canceled)
68. (canceled)
69. (canceled)
70. (canceled)
71. (canceled)
72. (canceled)
73. (canceled)
74. (canceled)
75. (canceled)
76. (canceled)
77. (canceled)
78. (canceled)
79. (canceled)
80. (canceled)
81. (canceled)
82. (canceled)
83. (canceled)
84. (canceled)
85. (canceled)
86. (canceled)
87. A pharmaceutical formulation comprising a blend of an immediate release component comprising APAP and an extended release component comprising optional APAP wherein when said formulation is administered to a subject for the treatment of pain for at least 8 hours, providing said formulation is not in the form of a bi-layer tablet.
88. (canceled)
89. (canceled)
90. (canceled)
91. (canceled)
92. (canceled)
93. A method of treating pain in a subject in need of such treatment comprising administering a pharmaceutically effective amount of a pharmaceutical formulation of claim 1.
94. A method of treating pain and a disease state resulting elevated histamine levels in a subject in need of such treatment comprising administering a pharmaceutically effective amount of a pharmaceutical formulation comprising an immediate release component, an extended release component, APAP, and an antihistimine wherein, when said formulation is administered to a subject, said formulation provides eight-hour bioequivalence of APAP compared to two consecutive administrations of one-half equivalent dose concentrations of APAP at a four-hour interval.
95. A method of treating pain and symptoms of respiratory illness in a subject in need of such treatment comprising administering a pharmaceutically effective amount of a pharmaceutical formulation comprising an immediate release component, an extended release component, APAP and one or more optional decongestants, one or more optional antitussives, and one or more expectorants wherein, when said formulation is administered to a subject, said formulation provides eight-hour bioequivalence of APAP compared to two consecutive administrations of one-half equivalent dose concentrations of APAP at a four-hour interval.
96. (canceled)